Gürler, F. Et Al. 2022. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. Anti-Cancer Drugs , vol.33, no.1 , 477-485.

Gürler, F., İlhan, A., Güven, D. C., Turhan, O., Kurt İnci, B., Sütçüoğlu, O., ... Yildiz, F.(2022). Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment. Anti-Cancer Drugs , vol.33, no.1, 477-485.

Gürler, FATİH Et Al. "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment," Anti-Cancer Drugs , vol.33, no.1, 477-485, 2022

Gürler, FATİH Et Al. "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment." Anti-Cancer Drugs , vol.33, no.1, pp.477-485, 2022

Gürler, F. Et Al. (2022) . "Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment." Anti-Cancer Drugs , vol.33, no.1, pp.477-485.

@article{article, author={FATİH GÜRLER Et Al. }, title={Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment}, journal={Anti-Cancer Drugs}, year=2022, pages={477-485} }